Rotavirus & Adenovirus Antigen Rapid Test Cassette (Colloidal Gold) Stool-based rapid antigen testing sits between clinical workflow and consumable supply planning. Pack configuration is the first procurement decision. The Rotavirus & Adenovirus Antigen Rapid Test Cassette (Colloidal Gold) is a lateral flow immunochromatographic assay. It provides qualitative detection of rotavirus antigen and adenovirus antigen in human feces, intended as a screening aid rather than a standalone diagnosis. Guoke Medical lists the product under code GKPD041 with pack sizes of 1, 10, 20, 25, 40, or 50 tests per box. The supplied text marks it for professional use only and requires results to be read alongside other clinical information available to the physician.

The study protocol and the statistical analysis plan are available in the Supplementary Information. The raw data are protected and are not publicly available due to applicable data privacy laws. Additional de-identified clinical trial data that support the findings of this study may be requested to the corresponding authors for research purposes consistent with those for which patients provided consent. Requests must specify the intended use of the data and will be assessed based on consistency with the original patient consent, applicable data privacy laws and ethical requirements. Data sharing requests will receive a response within 4 weeks of submission. If approved, data will be provided in de-identified form, with no personally identifiable information. Source data are provided with this paper. Authors and Affiliations Medical Oncology Department, Hospital Universitario 12 de Octubre (IIS Imas12), UCM, Madrid, Spain Rocio Garcia-Carbonero Miguel Servet University Hospital, Zaragoza, Spain Roberto Pazo Cid Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain Roberto Pazo Cid Medical Oncology Department, Clínic Barcelona Comprehensive Cancer Center, Hospital Clínic Barcelona, Barcelona, Spain Teresa Macarulla Translational Oncology in Upper Gastrointestinal Cancer Group, IDIBAPS, Barcelona, Spain Teresa Macarulla Departament of Medicine, University of Barcelona, Barcelona, Spain Teresa Macarulla Medical Oncology Department, ICO...

Immediate/long-term protective immunity in mice were evaluated by combining live-attenuated and trivalent vector-based plague vaccines. Immunization with either 2-dose prime-pull or 1-dose simultaneous administration elicited long-term immunity and complete protection against pneumonic plague. Simultaneous vaccination also provided immediate protection against bubonic/pneumonic challenges, thus suitable for reactive and preventive use.

Zoonotic visceral leishmaniasis caused by Leishmania infantum is the most severe clinical form of leishmaniasis and remains endemic in multiple regions, where it can be fatal if untreated. Domestic dogs act as the main urban reservoirs, sustaining zoonotic transmission. This study evaluated the immunogenicity and ability to reduce parasite burden of homologous and heterologous vaccination regimens based on the Leishmania amastigote A2 antigen administered as a recombinant adenovirus vector...

We write to the editorial team regarding the recently published paper “Randomized clinical trials of COVID-19 vaccines: Do adenovirus-vector vaccines have beneficial non-specific effects?”1 by Benn et...

Moreno and colleagues report a pharmacologically controllable oncolytic adenovirus platform that improves systemic tumor delivery by mesenchymal stem cells. By temporally regulating viral replication during trafficking while preserving full oncolytic activity at the tumor site, this strategy overcomes a key limitation of current cell-based virotherapies and enhances their translational potential.

Author Summary Ebola virus causes death, fear, and economic disruption during outbreaks. It is a concern worldwide as a natural pathogen and a bioterrorism agent, and has caused death to residents and...

Researchers have uncovered why a rare blood clotting disorder can occur after certain COVID-19 vaccines or adenovirus infections. The immune system can mistakenly target a normal blood protein (PF4) a...

Systemic delivery of oncolytic viruses (OVs) remains a central challenge in the field of oncolytic virotherapy.1 OVs selectively kill cancer cells while inducing antitumor immunity,2,3,4 but when administered intravenously, they must survive serum factors and host innate defenses, including neutralizing antibodies, before reaching tumors.1,5,6 For oncolytic adenovirus (oAD)-based therapies, natural immunoglobulin M (IgM) has generally been viewed as part of this barrier, promoting early viral neutralization and thus limiting viral bioavailability.

Vigorous vaccination programs against SARS-CoV-2-causing Covid-19 are the major chance to fight this dreadful pandemic. The currently administered vaccines depend on adenovirus DNA vectors or on SARS-CoV-2 mRNA that might become reverse transcribed ...

“Groundbreaking” study uncovers why adenovirus-based shots caused life-threatening blood clots and bleeding in some people

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019; in rare ca...